Molecular signatures linked with aggressive behavior in basal cell carcinoma: A report of 6 cases

American Journal of Dermatopathology

Volumn 32, Issue 6, 2010, Pages 550-556

  Fernandes, Helen ^a   Fernandes, Neil ^b   Bhattacharya, Siddharth ^a   Chen, Wen ^a   Seth, Anjali ^a   Hameed, Meera ^a   Mirani, Neena ^a   Lambert, W Clark ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

aggressive; allelic loss; basal cell carcinoma; cytokines; proinflammatory

Indexed keywords

DNA; FORMALDEHYDE; INTERLEUKIN 10; PARAFFIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGGRESSION; ARTICLE; BASAL CELL CARCINOMA; CANCER CLASSIFICATION; CHROMOSOME 9Q; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENETIC LINKAGE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, BASAL CELL; CHROMOSOMES, HUMAN, PAIR 9; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-10; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955175978     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181ca0ac2     Document Type: Article

References (36)

1. Saldanha G, Fletcher G, Slater DN. Basal cell carcinoma: a dermatopa- thological and molecular review. Br J Dermatol. 2003;148:195-202.
2. Walling H, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23:389-402.
3. Crowson A. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(Suppl 2):S127-S147.
4. Ramachandran S, Fryer AA, Smith A, et al. Cutaneous basal cell carcinomas: distinct host factors are associated with the development oftumors on the trunk and on the head and neck. Cancer. 2001;92: 354-358.
5. Hutchin M, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005;19:214-223.
6. Rubin A, Elbert HC, Desiree R. Basal-cell carcinoma. N Engl J Med. 2005;353:2262-2269.
7. Holikova Z, Massi D, Lotti T, et al. Insight into the pathogenesis of sporadic basal cell carcinoma. Int J Dermatol. 2004;43:865-869.
8. Taipale J, Cooper MK, Maiti T, et al. Patched acts catalytically to suppress the activity of Smoothened. Nature. 2002;418:892-897.
9. Couve-Privat S, Le Bret M, Traiffort E, et al. Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. Cancer Res. 2004;64:3559-3565.
10. O'Driscoll L, McMorrow J, Doolan P, et al. Investigation of the molecular profile of basal cell carcinoma using whole genome microarray. Mol Cancer. 2006;5:74-82.
11. Ashton K, Carless MA, Griffiths LR. Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer. 2005;43:239-248.
12. Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. 1999;41:143-164.
13. Shen T, Park WS, Boni R, et al. Detection of loss of heterozygosity on chromosome 9q22.3 in microdissected sporadic basal cell carcinoma. Hum Pathol. 1999;30:284-287.
14. Gailani M, Leffell DJ, Ziegler A, et al. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst. 1996;88:349-354.
15. Aswald J, Lipton JH, Aswald S, et al. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukaemia. Cytokines Cell Mol Ther. 2002;7:143-149.
16. Budhu AWX. The role of cytokines in hepatocellular carcinoma. JLeukoc Biol. 2006;80:1197-1213.
17. Hajeer A, Lear JT, Ollier WE, et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol. 2000;142:441-445.
18. Szlosarek P, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565-573.
19. Alamartine E, Berthoux P, Mariat C, et al. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol. 2003;120:99-103.
20. Howell W, Turner SJ, Bateman AC, et al. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2:25-31. (Pubitemid 33674866)
21. Wilson A, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195-3199.
22. Fernandes H, Koneru B, Fernandes N, et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation. 2002;73:1886-1891.
23. Canzian F, Salovaara R, Hemminki A, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 1996; 56:3331-3337.
24. Turner D, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
25. Soysal HGMD, Soysal EMD, Markoc FMD, et al. Basal cell carcinoma of the eyelids and periorbital region in a turkish population. Ophthal Plast Reconstr Surg. 2008;24:201-206.
26. Daya-Grosjean L, Couve-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett. 2005;225:181-192.
27. Danaee H, Karagas MR, Kelsey KT, et al. Allelic loss at drosophila patched gene is highly prevalent in basal and squamous cell carcinomas of the skin. J Invest Dermatol. 2006;126:1152-1158.
28. Sironi E, Cerri A, Tomasini D, et al. Loss of heterozygosity on chromosome 4q32-35 in sporadic basal cell carcinomas: evidence for the involvement of p33ING2/ING1L and SAP30 genes. J Cutan Pathol. 2004;31:318-322.
29. Teh M, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveilsuniparental disomy as a key somatic event. Cancer Res. 2005;65:8597-8603.
30. Fiorentino DFMT. Two types of mouse T helper cell. IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081-2095.
31. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. JNutr. 2007;137:194S-199S.
32. Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifac- torial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci. 2003;24:284-289.
33. Skov L, Allen MH, Bang B, et al. Basal cell carcinoma is associated with high TNF-alpha release but nor with TNF-alpha polymorphism at position-308. Exp Dermatol. 2003;12:772-776.
34. Leverkus M, Neumann, M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000;60:553-559.
35. Randle H. Basal cell carcinoma. Identification and treatment of the high- risk patient. Dermatol Surg. 1996;22:255-261.
36. Telfer N, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;158:35-48.